Reading ALDX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ALDX free→Reading ALDX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ALDX free→QuarterlyIQ Insights · ALDX
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (d) On June 9, 2026, following Aldeyra Therapeutics, Inc.’s (the “Company”) 2026 annual meeting of stockholders (the “2026 Annual Meeting”), and based upon the recommendation of the Nominating/Corporate Governance Committee of the Board of Directors (the “Board”), the Board appointed Darlene Deptula-Hicks as a Class III director, with her initial t…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On April 20, 2026, Martin J. Joyce, a member of the Board of Directors of Aldeyra Therapeutics, Inc. (“Aldeyra”), notified Aldeyra of his decision to not stand for re-election at the upcoming 2026 annual meeting of stockholders (the “2026 Annual Meeting”). Mr. Joyce will continue to serve until his term expires at the 2026 Annual Meeting. The d…
Other Events. As previously disclosed, Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) entered into that certain Loan and Security Agreement, dated as of March 25, 2019, by and among the Company, Helio Vision, LLC, the several banks and other financial institutions or entities from time to time parties thereto (the “Lenders”) and Hercules Capital, Inc., in its capacity as administrative agent and collateral agent for itself and the Lenders (as amended from time to time, the “Hercules…
of this Current Report on Form 8-K, on March 17, 2026, Aldeyra announced receipt of the 2026 Complete Response Letter. The 2026 Complete Response Letter stated that there is “a lack of substantial evidence consisting of adequate and well-controlled investigations … that the drug product will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in its proposed labeling” and that “the application has failed to demonstrate effica…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 23, 2025, Stephen G. Machatha, Ph.D. notified Aldeyra Therapeutics, Inc. (the “Company”) of his decision to voluntarily resign from his position as Chief Development Officer of the Company to pursue other professional opportunities. Dr. Machatha’s last day of employment with the Company will be on or before March 31, 2026 (such actual l…
of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing. Various statements to be made during the conference call and included in the Press Rel…
Regulation FD Disclosure. On November 13, 2025, Aldeyra Therapeutics, Inc. (“Aldeyra”) intends to make a slide presentation at its previously announced 2025 Research & Development Webcast (the “2025 Research and Development Webcast”). A copy of Aldeyra’s slide presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The furnishing of the attached slide presentation is not an admission as to the materiality of any information contain…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (d) On April 17, 2025, based upon the recommendation of the Nominating/Corporate Governance Committee of the Board of Directors (the “Board”) of Aldeyra Therapeutics, Inc. (“Aldeyra”), the Board elected William (Chip) Clark as a Class I director, with his initial term expiring at Aldeyra’s 2027 annual meeting of stockholders. In connection with Mr.…
Other Events. On April 3, 2025, Aldeyra issued the Press Release to announce that it had received a Complete Response Letter (“2025 Complete Response Letter”) from the U.S. Food & Drug Administration (“FDA”) regarding the Company’s resubmitted New Drug Application (“resubmitted NDA”) for reproxalap, an investigational drug candidate, for the treatment of dry eye disease. In the 2025 Complete Response Letter, the FDA stated that the NDA “failed to demonstrate efficacy in adequate and well cont…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.